James C. Greenwood

New reports indicate that drug prices are slowing compared to other healthcare costs.

Policies for patient access to life-saving therapies must keep pace with biomedical innovation.

Protecting intellectual property rights is vital to biopharmaceutical innovation.

Sound policies are needed to govern the substitution of interchangeable biologics.